Role of the aryl hydrocarbon receptor in Colon Neoplasia

Cancers

Volumn 7, Issue 3, 2015, Pages 1436-1446

  Xie, Guofeng ^a   Raufman, Jean Pierre ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Aryl hydrocarbon receptor; Colorectal cancer; TCDD; Xenobiotics

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE;

CANCER RISK; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CIRCADIAN RHYTHM; COLON CARCINOGENESIS; COLON TUMOR; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; ENTERITIS; ENZYME ACTIVATION; GENE TARGETING; HUMAN; MOUSE MODEL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 84938538411     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers7030847     Document Type: Review

References (70)

1. Siegel, R.; Desantis, C.; Jemal, A. Colorectal cancer statistics, 2014. CA Cancer J. Clin. 2014, 64, 104–117. [CrossRef] [PubMed]
2. Peery, A.F.; Dellon, E.S.; Lund, J.; Crockett, S.D.; McGowan, C.E.; Bulsiewicz, W.J.; Gangarosa, L.M.; Thiny, M.T.; Stizenberg, K.; Morgan, D.R.; et al. Burden of gastrointestinal disease in the united states: 2012 update. Gastroenterology 2012, 143. [CrossRef] [PubMed]
3. Edwards, B.K.; Ward, E.; Kohler, B.A.; Eheman, C.; Zauber, A.G.; Anderson, R.N.; Jemal, A.; Schymura, M.J.; Lansdorp-Vogelaar, I.; Seeff, L.C et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010, 116, 544–573. [CrossRef] [PubMed]
4. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60, 277–300. [CrossRef] [PubMed]
5. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 2015, 65, 5–29. [CrossRef] [PubMed]
6. Hewett, D.G.; Rex, D.K. The big picture: Does colonoscopy work? Gastrointest. Endosc. Clin. N. Am. 2015, 25, 403–413. [CrossRef] [PubMed]
7. Pignone, M.; Saha, S.; Hoerger, T.; Mandelblatt, J. Cost-effectiveness analyses of colorectal cancer screening: A systematic review for the U.S. Preventive services task force. Ann. Intern. Med. 2002, 137, 96–104. [CrossRef] [PubMed]
8. Corley, D.A. The future of colon cancer screening: What do we recommend and will it be too much, too little, or just right? Gastroenterology 2011, 141, 1956–1958. [CrossRef] [PubMed]
9. Baron, J.A.; Sandler, R.S.; Bresalier, R.S.; Quan, H.; Riddell, R.; Lanas, A.; Bolognese, J.A.; Oxenius, B.; Horgan, K.; Loftus, S et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006, 131, 1674–1682. [CrossRef] [PubMed]
10. Bertagnolli, M.M.; Eagle, C.J.; Zauber, A.G.; Redston, M.; Solomon, S.D.; Kim, K.; Tang, J.; Rosenstein, R.B.; Wittes, J.; Corle, D et al. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 2006, 355, 873–884. [CrossRef] [PubMed]
11. Helin-Salmivaara, A.; Saarelainen, S.; Gronroos, J.M.; Vesalainen, R.; Klaukka, T.; Huupponen, R. Risk of upper gastrointestinal events with the use of various nsaids: A case-control study in a general population. Scand. J. Gastroenterol. 2007, 42, 923–932. [CrossRef] [PubMed]
12. Kerr, D.J.; Dunn, J.A.; Langman, M.J.; Smith, J.L.; Midgley, R.S.; Stanley, A.; Stokes, J.C.; Julier, P.; Iveson, C.; Duvvuri, R et al. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N. Engl. J. Med. 2007, 357, 360–369. [CrossRef] [PubMed]
13. McGettigan, P.; Henry, D. Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase. JAMA 2006, 296, 1633–1644. [CrossRef] [PubMed]
14. Modjtahedi, H.; Essapen, S. Epidermal growth factor receptor inhibitors in cancer treatment: Advances, challenges and opportunities. Anticancer Drugs 2009, 20, 851–855. [CrossRef] [PubMed]
15. Overman, M.J.; Hoff, P.M. Egfr-targeted therapies in colorectal cancer. Dis. Colon Rectum 2007, 50, 1259–1270. [CrossRef] [PubMed]
16. Venook, A.P. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer 2005, 103, 2435–2446. [CrossRef] [PubMed]
17. Sipples, R. Common side effects of anti-egfr therapy: Acneform rash. Semin. Oncol. Nurs. 2006, 22, 28–34. [CrossRef] [PubMed]
18. Ohtake, F.; Fujii-Kuriyama, Y.; Kato, S. AhR acts as an E3 ubiquitin ligase to modulate steroid receptor functions. Biochem. Pharmacol. 2009, 77, 474–484. [CrossRef] [PubMed]
19. Adachi, Y.; Yamamoto, H.; Itoh, F.; Hinoda, Y.; Okada, Y.; Imai, K. Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut 1999, 45, 252–258. [CrossRef] [PubMed]
20. Hankinson, O. The aryl hydrocarbon receptor complex. Annu. Rev. Pharmacol. Toxicol. 1995, 35, 307–340. [CrossRef] [PubMed]
21. Carver, L.A.; Bradfield, C.A. Ligand-dependent interaction of the aryl hydrocarbon receptor with a novel immunophilin homolog in vivo. J. Biol. Chem. 1997, 272, 11452–11456. [PubMed]
22. Chen, H.S.; Perdew, G.H. Subunit composition of the heteromeric cytosolic aryl hydrocarbon receptor complex. J. Biol. Chem. 1994, 269, 27554–27558. [PubMed]
23. Ma, Q.; Whitlock, J.P Jr. A novel cytoplasmic protein that interacts with the ah receptor, contains tetratricopeptide repeat motifs, and augments the transcriptional response to 2,3,7,8-tetrachlorodibenzo-p-dioxin. J. Biol. Chem. 1997, 272, 8878–8884. [PubMed]
24. Denison, M.S.; Nagy, S.R. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu. Rev. Pharmacol. Toxicol. 2003, 43, 309–334. [CrossRef] [PubMed]
25. Nguyen, L.P.; Bradfield, C.A. The search for endogenous activators of the aryl hydrocarbon receptor. Chem. Res. Toxicol. 2008, 21, 102–116. [CrossRef] [PubMed]
26. Safe, S.; Lee, S.O.; Jin, U.H. Role of the aryl hydrocarbon receptor in carcinogenesis and potential as a drug target. Toxicol. Sci. 2013, 135, 1–16. [CrossRef] [PubMed]
27. Murray, I.A.; Patterson, A.D.; Perdew, G.H. Aryl hydrocarbon receptor ligands in cancer: Friend and foe. Nat. Rev. Cancer 2014, 14, 801–814. [CrossRef] [PubMed]
28. Bock, K.W.; Kohle, C. Ah receptor- and TCDD-mediated liver tumor promotion: Clonal selection and expansion of cells evading growth arrest and apoptosis. Biochem. Pharmacol. 2005, 69, 1403–1408. [CrossRef] [PubMed]
29. Knerr, S.; Schrenk, D. Carcinogenicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in experimental models. Mol. Nutr. Food Res. 2006, 50, 897–907. [CrossRef] [PubMed]
30. Chao, A.; Thun, M.J.; Connell, C.J.; McCullough, M.L.; Jacobs, E.J.; Flanders, W.D.; Rodriguez, C.; Sinha, R.; Calle, E.E. Meat consumption and risk of colorectal cancer. JAMA 2005, 293, 172–182. [CrossRef] [PubMed]
31. Kirkegaard, H.; Johnsen, N.F.; Christensen, J.; Frederiksen, K.; Overvad, K.; Tjonneland, A. Association of adherence to lifestyle recommendations and risk of colorectal cancer: A prospective danish cohort study. BMJ 2010, 341. [CrossRef] [PubMed]
32. Louis, P.; Hold, G.L.; Flint, H.J. The gut microbiota, bacterial metabolites and colorectal cancer. Nat. Rev. Microbiol. 2014, 12, 661–672. [CrossRef] [PubMed]
33. Bjeldanes, L.F.; Kim, J.Y.; Grose, K.R.; Bartholomew, J.C.; Bradfield, C.A. Aromatic hydrocarbon responsiveness-receptor agonists generated from indole-3-carbinol in vitro and in vivo: Comparisons with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Proc. Natl. Acad. Sci. USA 1991, 88, 9543–9547. [CrossRef] [PubMed]
34. Bonnesen, C.; Eggleston, I.M.; Hayes, J.D. Dietary indoles and isothiocyanates that are generated from cruciferous vegetables can both stimulate apoptosis and confer protection against DNA damage in human colon cell lines. Cancer Res. 2001, 61, 6120–6130. [PubMed]
35. Kim, Y.S.; Milner, J.A. Targets for indole-3-carbinol in cancer prevention. J. Nutr. Biochem. 2005, 16, 65–73. [CrossRef] [PubMed]
36. Potter, J.D.; Steinmetz, K. Vegetables, fruit and phytoestrogens as preventive agents. IARC Sci. Publ. 1996, 139, 61–90. [PubMed]
37. Jin, U.H.; Lee, S.O.; Sridharan, G.; Lee, K.; Davidson, L.A.; Jayaraman, A.; Chapkin, R.S.; Alaniz, R.; Safe, S. Microbiome-derived tryptophan metabolites and their aryl hydrocarbon receptor-dependent agonist and antagonist activities. Mol. Pharmacol. 2014, 85, 777–788. [CrossRef] [PubMed]
38. Zelante, T.; Iannitti, R.G.; Cunha, C.; de Luca, A.; Giovannini, G.; Pieraccini, G.; Zecchi, R.; D’Angelo, C.; Massi-Benedetti, C.; Fallarino, F et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 2013, 39, 372–385. [CrossRef] [PubMed]
39. Theodoratou, E.; Kyle, J.; Cetnarskyj, R.; Farrington, S.M.; Tenesa, A.; Barnetson, R.; Porteous, M.; Dunlop, M.; Campbell, H. Dietary flavonoids and the risk of colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 2007, 16, 684–693. [CrossRef] [PubMed]
40. Amakura, Y.; Tsutsumi, T.; Nakamura, M.; Kitagawa, H.; Fujino, J.; Sasaki, K.; Toyoda, M.; Yoshida, T.; Maitani, T. Activation of the aryl hydrocarbon receptor by some vegetable constituents determined using in vitro reporter gene assay. Biol. Pharm. Bull. 2003, 26, 532–539. [CrossRef] [PubMed]
41. Zhang, S.; Qin, C.; Safe, S.H. Flavonoids as aryl hydrocarbon receptor agonists/antagonists: Effects of structure and cell context. Environ. Health Perspect. 2003, 111, 1877–1882. [CrossRef] [PubMed]
42. Veeriah, S.; Kautenburger, T.; Habermann, N.; Sauer, J.; Dietrich, H.; Will, F.; Pool-Zobel, B.L. Apple flavonoids inhibit growth of HT29 human colon cancer cells and modulate expression of genes involved in the biotransformation of xenobiotics. Mol. Carcinog. 2006, 45, 164–174. [CrossRef] [PubMed]
43. Moon, R.T.; Kohn, A.D.; de Ferrari, G.V.; Kaykas, A. Wnt and beta-catenin signalling: Diseases and therapies. Nat. Rev. Genet. 2004, 5, 691–701. [CrossRef] [PubMed]
44. Clevers, H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127, 469–480. [CrossRef] [PubMed]
45. Markowitz, S.D.; Bertagnolli, M.M. Molecular origins of cancer: Molecular basis of colorectal cancer. N. Engl. J. Med. 2009, 361, 2449–2460. [CrossRef] [PubMed]
46. Kawajiri, K.; Kobayashi, Y.; Ohtake, F.; Ikuta, T.; Matsushima, Y.; Mimura, J.; Pettersson, S.; Pollenz, R.S.; Sakaki, T.; Hirokawa, T et al. Aryl hydrocarbon receptor suppresses intestinal carcinogenesis in apcmin/+ mice with natural ligands. Proc. Natl. Acad. Sci. USA 2009, 106, 13481–13486. [CrossRef] [PubMed]
47. Fan, Y.; Boivin, G.P.; Knudsen, E.S.; Nebert, D.W.; Xia, Y.; Puga, A. The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis. Cancer Res. 2010, 70, 212–220. [CrossRef] [PubMed]
48. Dolwick, K.M.; Schmidt, J.V.; Carver, L.A.; Swanson, H.I.; Bradfield, C.A. Cloning and expression of a human ah receptor cdna. Mol. Pharmacol. 1993, 44, 911–917. [PubMed]
49. Hayashi, S.; Watanabe, J.; Nakachi, K.; Eguchi, H.; Gotoh, O.; Kawajiri, K. Interindividual difference in expression of human ah receptor and related p450 genes. Carcinogenesis 1994, 15, 801–806. [CrossRef] [PubMed]
50. O’Donnell, E.F.; Kopparapu, P.R.; Koch, D.C.; Jang, H.S.; Phillips, J.L.; Tanguay, R.L.; Kerkvliet, N.I.; Kolluri, S.K. The aryl hydrocarbon receptor mediates leflunomide-induced growth inhibition of melanoma cells. PLoS ONE 2012, 7, e40926. [CrossRef] [PubMed]
51. Androutsopoulos, V.P.; Tsatsakis, A.M.; Spandidos, D.A. Cytochrome p450 cyp1a1: Wider roles in cancer progression and prevention. BMC Cancer 2009, 9, 187. [CrossRef] [PubMed]
52. Androutsopoulos, V.P.; Spyrou, I.; Ploumidis, A.; Papalampros, A.E.; Kyriakakis, M.; Delakas, D.; Spandidos, D.A.; Tsatsakis, A.M. Expression profile of cyp1a1 and cyp1b1 enzymes in colon and bladder tumors. PLoS ONE 2013, 8, e82487. [CrossRef] [PubMed]
53. Le Ferrec, E.; Lagadic-Gossmann, D.; Rauch, C.; Bardiau, C.; Maheo, K.; Massiere, F.; le Vee, M.; Guillouzo, A.; Morel, F. Transcriptional induction of cyp1a1 by oltipraz in human caco-2 cells is aryl hydrocarbon receptor- and calcium-dependent. J. Biol. Chem. 2002, 277, 24780–24787. [CrossRef] [PubMed]
54. Tompkins, L.M.; Li, H.; Li, L.; Lynch, C.; Xie, Y.; Nakanishi, T.; Ross, D.D.; Wang, H. A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cells. Biochem. Pharmacol. 2010, 80, 1754–1761. [CrossRef] [PubMed]
55. Villard, P.H.; Caverni, S.; Baanannou, A.; Khalil, A.; Martin, P.G.; Penel, C.; Pineau, T.; Seree, E.; Barra, Y. PPARalpha transcriptionally induces ahr expression in Caco-2, but represses AhR pro-inflammatory effects. Biochem. Biophys. Res. Commun. 2007, 364, 896–901. [CrossRef] [PubMed]
56. Haarmann-Stemmann, T.; Bothe, H.; Abel, J. Growth factors, cytokines and their receptors as downstream targets of arylhydrocarbon receptor (AhR) signaling pathways. Biochem. Pharmacol. 2009, 77, 508–520. [CrossRef] [PubMed]
57. Puga, A.; Ma, C.; Marlowe, J.L. The aryl hydrocarbon receptor cross-talks with multiple signal transduction pathways. Biochem. Pharmacol. 2009, 77, 713–722. [CrossRef] [PubMed]
58. Gomez-Duran, A.; Carvajal-Gonzalez, J.M.; Mulero-Navarro, S.; Santiago-Josefat, B.; Puga, A.; Fernandez-Salguero, P.M. Fitting a xenobiotic receptor into cell homeostasis: How the dioxin receptor interacts with tgfbeta signaling. Biochem. Pharmacol. 2009, 77, 700–712. [CrossRef] [PubMed]
59. De Oliveira, S.K.; Smolenski, A. Phosphodiesterases link the aryl hydrocarbon receptor complex to cyclic nucleotide signaling. Biochem. Pharmacol. 2009, 77, 723–733. [CrossRef] [PubMed]
60. Rowlands, J.C.; Gustafsson, J.A. Aryl hydrocarbon receptor-mediated signal transduction. Crit. Rev. Toxicol. 1997, 27, 109–134. [CrossRef] [PubMed]
61. Xie, G.; Peng, Z.; Raufman, J.P. Src-mediated aryl hydrocarbon and epidermal growth factor receptor cross talk stimulates colon cancer cell proliferation. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 302, G1006–G1015. [CrossRef] [PubMed]
62. Dietrich, C.; Kaina, B. The aryl hydrocarbon receptor (AhR) in the regulation of cell-cell contact and tumor growth. Carcinogenesis 2010, 31, 1319–1328. [CrossRef] [PubMed]
63. Monteleone, I.; MacDonald, T.T.; Pallone, F.; Monteleone, G. The aryl hydrocarbon receptor in inflammatory bowel disease: Linking the environment to disease pathogenesis. Curr. Opin. Gastroenterol. 2012, 28, 310–313. [CrossRef] [PubMed]
64. Monteleone, I.; Rizzo, A.; Sarra, M.; Sica, G.; Sileri, P.; Biancone, L.; MacDonald, T.T.; Pallone, F.; Monteleone, G. Aryl hydrocarbon receptor-induced signals up-regulate il-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology 2011, 141. [CrossRef] [PubMed]
65. Furumatsu, K.; Nishiumi, S.; Kawano, Y.; Ooi, M.; Yoshie, T.; Shiomi, Y.; Kutsumi, H.; Ashida, H.; Fujii-Kuriyama, Y.; Azuma, T et al. A role of the aryl hydrocarbon receptor in attenuation of colitis. Dig. Dis. Sci. 2011, 56, 2532–2544. [CrossRef] [PubMed]
66. Ji, T.; Xu, C.; Sun, L.; Yu, M.; Peng, K.; Qiu, Y.; Xiao, W.; Yang, H. Aryl hydrocarbon receptor activation down-regulates IL-7 and reduces inflammation in a mouse model of DSS-induced colitis. Dig. Dis. Sci. 2015, 60, 1958–1066. [CrossRef] [PubMed]
67. Ullman, T.A.; Itzkowitz, S.H. Intestinal inflammation and cancer. Gastroenterology 2011, 140, 1807–1816. [CrossRef] [PubMed]
68. Ikuta, T.; Kobayashi, Y.; Kitazawa, M.; Shiizaki, K.; Itano, N.; Noda, T.; Pettersson, S.; Poellinger, L.; Fujii-Kuriyama, Y.; Taniguchi, S et al. Asc-associated inflammation promotes cecal tumorigenesis in aryl hydrocarbon receptor-deficient mice. Carcinogenesis 2013, 34, 1620–1627. [CrossRef] [PubMed]
69. Anderson, G.; Beischlag, T.V.; Vinciguerra, M.; Mazzoccoli, G. The circadian clock circuitry and the AhR signaling pathway in physiology and pathology. Biochem. Pharmacol. 2013, 85, 1405–1416. [CrossRef] [PubMed]
70. Mazzoccoli, G.; Vinciguerra, M.; Papa, G.; Piepoli, A. Circadian clock circuitry in colorectal cancer. World J. Gastroenterol. 2014, 20, 4197–4207. [CrossRef] [PubMed]